Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer
- 4 August 2022
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1877 (5) , 188775
Abstract
No abstract availableKeywords
Funding Information
- China Postdoctoral Science Foundation (2020M681893, 82172908)
- Natural Science Foundation of Zhejiang Province (LQ21H160027)
- National Natural Science Foundation of China (82100542)
This publication has 129 references indexed in Scilit:
- Processes of Care in the Multidisciplinary Treatment of Gastric CancerJAMA Surgery, 2014
- Inhibition of Dendritic Cell Maturation by the Tumor Microenvironment Correlates with the Survival of Colorectal Cancer Patients following Bevacizumab TreatmentMolecular Cancer Therapeutics, 2012
- Differentiation and gene expression profile of tumor-associated macrophagesSeminars in Cancer Biology, 2012
- Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell–expressed FasLBlood, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of CancerCancer Research, 2010
- Interferon-γ and interleukin-4 reciprocally regulate CD8 expression in CD8+T cellsProceedings of the National Academy of Sciences, 2008
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007
- Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidinesJournal of Clinical Oncology, 2006
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004